The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers
BRCA2 germline-mutated patients obtained significantly greater benefit from olaparib compared to BRCA1-mutated patients. PFS benefit from niraparib (primary or recurrent setting) is comparable to clinical trials. There was no difference in benefit between niraparib and rucaparib in the recurrent setting.
Authors
- Benjamin W. Wormald (ORCID: https://orcid.org/0000-0001-6464-5391)
- Srinivasan Madhusudan (ORCID: https://orcid.org/0000-0002-5354-5480)
- Keith D Buxton
- David Nunns
- Navin Mathiyalagan
- Muhammad Adeel Sarwar
- A Radford
- Anjana Anand (ORCID: https://orcid.org/0000-0002-2856-4129)
- Bahaaeldin Baraka (ORCID: https://orcid.org/0000-0002-7133-5209)
- Maryam Al-Ani
- Ketankumar Gajjar (ORCID: https://orcid.org/0000-0001-8459-0252)
- Karin Williamson (ORCID: https://orcid.org/0000-0002-1054-5691)
- Santhanam Sundar (ORCID: https://orcid.org/0000-0003-0850-5161)
- Lalith Seneviratne
- Ashvina Segaran
- Wafaa Abuzahra
Institutions
- Nottingham University Hospitals NHS Trust (GB)
- University of Nottingham (GB)
- Nottingham City Hospital (GB)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3390/cancers17213591
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Nottingham